Oppenheimer Asset Management Inc. Decreases Stake in Masimo Corporation $MASI

Oppenheimer Asset Management Inc. lowered its position in shares of Masimo Corporation (NASDAQ:MASI) by 47.7% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 1,733 shares of the medical equipment provider’s stock after selling 1,583 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Masimo were worth $292,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Masimo by 0.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,371 shares of the medical equipment provider’s stock worth $1,894,000 after purchasing an additional 66 shares during the period. Xponance Inc. boosted its holdings in Masimo by 1.1% in the 1st quarter. Xponance Inc. now owns 7,101 shares of the medical equipment provider’s stock worth $1,183,000 after acquiring an additional 76 shares during the period. Deutsche Bank AG boosted its holdings in Masimo by 1.5% in the 1st quarter. Deutsche Bank AG now owns 6,309 shares of the medical equipment provider’s stock worth $1,051,000 after acquiring an additional 92 shares during the period. State of Michigan Retirement System boosted its holdings in Masimo by 1.0% in the 1st quarter. State of Michigan Retirement System now owns 10,596 shares of the medical equipment provider’s stock worth $1,765,000 after acquiring an additional 100 shares during the period. Finally, Securian Asset Management Inc. boosted its holdings in Masimo by 3.0% in the 1st quarter. Securian Asset Management Inc. now owns 3,433 shares of the medical equipment provider’s stock worth $572,000 after acquiring an additional 100 shares during the period. Hedge funds and other institutional investors own 85.96% of the company’s stock.

Masimo Stock Performance

Masimo stock opened at $140.65 on Monday. The stock has a market cap of $7.64 billion, a P/E ratio of -16.51 and a beta of 1.28. The company has a current ratio of 2.14, a quick ratio of 1.61 and a debt-to-equity ratio of 0.57. The stock has a 50 day moving average of $144.80 and a 200-day moving average of $154.12. Masimo Corporation has a 52 week low of $133.70 and a 52 week high of $194.88.

Masimo (NASDAQ:MASI) last released its earnings results on Thursday, June 20th. The medical equipment provider reported $1.42 EPS for the quarter. The company had revenue of $617.00 million during the quarter. Masimo had a positive return on equity of 26.54% and a negative net margin of 24.85%. On average, analysts expect that Masimo Corporation will post 4.1 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on MASI shares. Piper Sandler upped their price target on Masimo from $200.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 6th. Zacks Research cut Masimo from a “strong-buy” rating to a “hold” rating in a report on Friday, October 24th. BTIG Research restated a “buy” rating and issued a $198.00 price target on shares of Masimo in a report on Thursday, September 11th. Weiss Ratings restated a “sell (d)” rating on shares of Masimo in a report on Wednesday, October 8th. Finally, Wall Street Zen upgraded Masimo from a “hold” rating to a “buy” rating in a research note on Tuesday, October 14th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $194.60.

Insider Activity at Masimo

In other Masimo news, Director William R. Jellison bought 3,000 shares of Masimo stock in a transaction dated Monday, August 11th. The stock was bought at an average cost of $145.98 per share, for a total transaction of $437,940.00. Following the purchase, the director owned 4,790 shares in the company, valued at $699,244.20. This represents a 167.60% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 9.70% of the company’s stock.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.